Publications by authors named "Iwona Zerda"
Objective: Currently there are no disease-specific approved therapies for non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH); however, several treatments are under development. This study aimed to estimate the cost-effectiveness of hypothetical innovative therapies compared with lifestyle intervention alone and combined with pioglitazone, and assess the health economic consequences of their future availability for patients.
Methods: A Markov cohort model was developed, considering fourteen disease health states and one absorbing state representing death.
Article Synopsis
- Research on using biological drugs for psoriasis in women who are planning to conceive, pregnant, or breastfeeding is limited.
- The paper reviews guidelines from over 40 sources and highlights that certolizumab pegol is favored for women planning to conceive and recommended as a first-line treatment during pregnancy.
- TNF-α inhibitors, particularly certolizumab pegol, are considered the safest option for treating psoriasis in these patients, but a risk-benefit analysis is essential before proceeding with any treatment during pregnancy or lactation.
Article Synopsis
- Epilepsy impacts nearly 50 million people globally, creating significant financial burdens on both healthcare systems and patients.
- A study in Poland assessed the direct and indirect costs of epilepsy from 2014 to 2018, revealing a decrease in total costs over time, with indirect costs being the most significant contributor.
- Findings showed that while total epilepsy-related costs dropped from EUR 410 million in 2014 to EUR 361 million in 2018, indirect costs accounted for a large portion, mostly due to long-term absenteeism, emphasizing the need for targeted attention from policymakers.